These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34666379)

  • 1. INOVASIA Study: A Randomized Open Controlled Trial to Evaluate Pravastatin to Prevent Preeclampsia and Its Effects on sFlt1/PlGF Levels.
    Akbar MIA; Yosediputra A; Pratama RE; Fadhilah NL; Sulistyowati S; Amani FZ; Ernawati E; Dachlan EG; Angsar MD; Dekker G
    Am J Perinatol; 2024 Feb; 41(3):300-309. PubMed ID: 34666379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia.
    Binder J; Palmrich P; Kalafat E; Haberl C; Schirwani N; Pateisky P; Khalil A
    Ultrasound Obstet Gynecol; 2023 Dec; 62(6):843-851. PubMed ID: 37265117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
    PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INOVASIA Study: A Multicenter Randomized Clinical Trial of Pravastatin to Prevent Preeclampsia in High-Risk Patients.
    Akbar MIA; Azis MA; Riu DS; Wawengkang E; Ernawati E; Bachnas MA; Sulistyowati S; Dachlan EG; Mose JC; Dekker G
    Am J Perinatol; 2024 Jul; 41(9):1203-1211. PubMed ID: 35292944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Ultrasound Obstet Gynecol; 2022 Feb; 59(2):192-201. PubMed ID: 34165863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.
    Sokratous N; Wright A; Syngelaki A; Kakouri E; Laich A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 Jan; 63(1):88-97. PubMed ID: 37724582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
    Jääskeläinen T; Heinonen S; Hämäläinen E; Pulkki K; Romppanen J; Laivuori H;
    Pregnancy Hypertens; 2018 Oct; 14():252-259. PubMed ID: 29803331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population.
    Kumar N; Das V; Agarwal A; Agrawal S
    AJOG Glob Rep; 2023 May; 3(2):100177. PubMed ID: 36911235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction.
    Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive value of the sFlt1/PlGF ratio for the diagnosis of preeclampsia in high-risk patients].
    Husse S; Gottschlich A; Schrey S; Stepan H; Hoffmann J
    Z Geburtshilfe Neonatol; 2014 Feb; 218(1):34-41. PubMed ID: 24595913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.
    Chaiworapongsa T; Romero R; Savasan ZA; Kusanovic JP; Ogge G; Soto E; Dong Z; Tarca A; Gaurav B; Hassan SS
    J Matern Fetal Neonatal Med; 2011 Oct; 24(10):1187-207. PubMed ID: 21827221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.